AMAZENTIS
17.5.2022 17:06:07 CEST | Business Wire | Press release
Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed clinical and translational journal Cell Reports Medicine published new clinical results showing the muscle health benefits of the gut microbiome postbiotic Urolithin A. Age-associated muscle decline can start as early as 40 years old and there are currently no effective interventions to counteract it other than exercise.
This milestone study showed that daily intake of Amazentis’ proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months. These findings further validate Mitopure’s benefits for muscle and mitochondrial health and show it is safe and well tolerated. Mitopure works by supporting the cells’ ability to renew their powerplants, the mitochondria, during the aging process. Muscles have a high demand for energy and there are a very large number of mitochondria in muscle cells.
Previous research showed that Mitopure improved muscle endurance, reduced inflammation, and resulted in healthier mitochondrial function in older adults 65 to 90 years old. This new double-blind, placebo-controlled trial in middle-aged adults 40 to 64 years old (n=88) was conducted in London, Ontario, Canada following approvals from Health Canada and an independent IRB. Participants were randomized to receive daily supplementation with either 500mg, 1,000mg Mitopure or placebo for 4 months. Muscle strength, exercise performance tests and biomarkers of healthy mitochondrial function and inflammation in skeletal muscle biopsies and blood plasma were assessed at baseline, 2 months and 4 months.
- Two measures of skeletal muscle strength were improved in the supplemented groups compared to the placebo group. Muscle strength in the hamstring skeletal muscle was significantly increased in both 500mg (+12%) and 1,000mg groups (+9.8%). Muscle strength during knee flexion was also significantly improved at both 500mg (+10.6%) and 1,000mg doses (+10.5%)
- Clinically meaningful improvements on aerobic endurance (+ 10% in peak oxygen consumption [VO2]), physical performance (+ 33 meters on the 6 min walk test), and power output (+5%) were observed in the 1,000mg group, though not statistically significant
- The blood tests and biopsies showed a significant improvement in biomarkers of healthy mitochondrial function and reduced inflammation
“These results are exciting because this is the first in human demonstration that Urolithin A repairs the mitochondria via mitophagy and can translate to meaningful physiological benefits. Furthermore, the improvement in strength and exercise-performance occurred in the absence of any changes to participants exercise routine,” explained Johan Auwerx, MD, PhD, co-author and Professor at the Swiss Federal Institute of Technology EPFL.
This is an important discovery in longevity and muscle health research. Aging is associated with a decline in mitochondrial function which can lead to reduced exercise capacity, muscle endurance and strength. Urolithin A is the first and only compound that has been clinically shown to improve muscle function by renewing the mitochondria through a potent biological quality control mechanism called mitophagy. By activating this important biological pathway, Mitopure promotes healthy aging and improved muscle health and performance.
“This study further validates the role of mitochondrial health as an important pillar of vitality and shows Mitopure is a first in class nutrient that meaningfully impacts muscle health. We are proud to offer this proprietary form of Urolithin A in our Timeline® brand and inside Nestlé Health Science products,” said Chris Rinsch, CEO and Co-Founder of Amazentis. “We remain committed to pioneering clinically validated products that optimize cellular health with the mission of keeping millions of people healthier for longer”.
In addition, Amazentis also announced that Dr. Eric Verdin has joined the Amazentis scientific advisory board. Dr. Verdin is the president and chief executive officer of the Buck Institute for Research on Aging and he has dedicated his career to studying longevity with the goal of transforming everyone into healthy centenarians.
“Mitochondrial decline is a key hallmark of aging and poor metabolic health. This study is an important milestone and shows that Urolithin A could be a gamechanger in our field.” said. Dr. Eric Verdin.
Doi: 10.1016/j.xcrm.2022.100633
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure™ Urolithin A in top peer reviewed scientific journals including Nature Medicine
(doi:10.1038/nm.4132), Nature Metabolism
(doi: 10.1038/s42255-019-0073-4), JAMA Network Open
(doi:10.1001/jamanetworkopen.2021.44279) and European Journal of Clinical Nutrition
(https://doi.org/10.1038/s41430-021-00950-1
). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™ linked to mitochondrial and cellular health. For more information on Amazentis, please visit www.amazentis.com
.
About Mitopure™
Mitopure™ is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure™ has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure™ has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure™ has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com
.
About Timeline®
Timeline® Nutrition is brought to you by the inventors of Mitopure™. This novel, science-first brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of clinically validated nutritional products to optimize cellular health. For more information, please visit www.timelinenutrition.com
.
Related Links
https://www.timelinenutrition.com
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005659/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply and IEO Launch Collaboration to Co-Develop and Train Domain-Specific Large Language Models for Oncology4.6.2026 10:10:00 CEST | Press release
Reply [EXM, STAR: REY] and the European Institute of Oncology (IEO) have launched a collaboration focused on the co-development and training of domain-specific Large Language Models for oncology. The initiative brings together Reply’s expertise in building frontier generative models grounded in enterprise knowledge with the IEO’s clinical expertise and data assets to develop models tailored to highly complex oncology settings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604488955/en/ Reply and the European Institute of Oncology (IEO) have launched a collaboration focused on the co-development and training of domain-specific Large Language Models for oncology. As a first step, the IEO’s clinical teams and Information Systems department are working with a multidisciplinary Reply team with deep expertise in healthcare and LLM specialisation to define and prioritise the use cases that will guide development, while also map
UK AI Minister Kanishka Narayan Joins The AI Summit London as 10th Anniversary Agenda Expands Across Enterprise AI, Innovation and Policy4.6.2026 10:00:00 CEST | Press release
London Tech Week's flagship AI event will feature 300 speakers, live AI demonstrations, startup pitch competitions, executive training and the National AI Awards The AI Summit London today revealed the full agenda for its highly anticipated 10th anniversary edition, delivering its most expansive and future-focused programme to date. Taking place 10–11 June at Tobacco Dock as the headline AI event of London Tech Week 2026, the Summit expects more than 5,000 attendees, 300 speakers, 100+ sponsors and exhibitors, and a special executive presentation from Kanishka Narayan, Minister for AI and Online Safety, Department for Science, Innovation and Technology, across two days dedicated to the commercial realities and transformative potential of artificial intelligence. The 10th anniversary has been designed to move the conversation beyond experimentation and into enterprise-wide execution. New in 2026, the programme introduces The AI Impact Arena, delivering focused briefings and live demos,
Corona Launches 2026 Beach 100 Guide, Invites The World To Explore The Outdoors This Summer4.6.2026 10:00:00 CEST | Press release
Ahead of World Oceans Day, the global beach authority returns with a list of new locations, over 300,000 Tripadvisor experiences, and dedicated beach grants as part of its “This is Living” platform Corona, the world’s most valuable beer brand1, today announced the return of its annual global beach guide, the 2026 Corona Beach 100, ahead of World Oceans Day on June 8. The highly anticipated second edition spotlights 100 breathtaking and varied ocean-front destinations around the world while celebrating the natural ecosystems and local communities that help bring them to life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604412899/en/ 2026 Corona Beach 100 - Legzira Beach, Morocco Connected to Corona’s “This Is Living” platform, which invites consumers to step outside and live life to the fullest this summer, the 2026 guide features 27 new beaches, hundreds of localized Tripadvisor travel experiences inspired by the world
Lantern Expands Its Platform for Solving the Data Trust Problem with Strategic Acquisition and Key Executive Hires4.6.2026 10:00:00 CEST | Press release
Lantern Acquires Freyda to Create the First End-to-End Data Assurance Platform for Private Markets Lantern Limited (“Lantern”), the data assurance platform for private markets, announced today a strategic acquisition, expanded platform capabilities, and key leadership additions to address one of private markets biggest operational challenges: transforming fragmented, disconnected data across multiple sources into trusted, actionable intelligence. Private markets run on data, yet much of that data remains siloed, trapped in PDFs, and processed through highly manual workflows across both fund managers and investors. While GPs have increasingly modernized how they manage and report fund information internally, LPs still spend billions of dollars each year manually extracting, normalizing, and reconciling data from capital notices, quarterly statements, and other fund documents. With the acquisition of Freyda Limited (“Freyda”), one of the leading AI document intelligence platforms for ins
KAYTUS Launches MotusAI Enterprise Token Management Platform4.6.2026 09:02:00 CEST | Press release
KAYTUS, a leading provider of AI infrastructure and liquid cooling solutions, today announced the launch of enterprise-grade token management capabilities within MotusAI, enabling organizations to rapidly build, deploy, and operate secure on-premises AI token platform. This pioneering infrastructure enhancement transforms traditional GPU hardware into a unified, governable, and highly efficient internal token service ecosystem. By enabling rapid private deployment, MotusAI provides enterprises with a cost-competitive foundation for accelerating the scale-up of enterprise-grade AI agents while ensuring strong data privacy. Why Enterprises Must Build a Private Token Management Platform Now? As enterprise AI evolves from isolated model-based tools to interconnected AI agent systems that enable deep workflow automation, tokens are emerging as the fundamental “computing currency” of the modern organization. While standard LLM queries typically involve predictable, one-off inference requests
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom